New axSpA Criteria: Who gets left out?
Dr. Nelly Ziade discusses abstract OP0236, OP0239, and POS0190 EULAR 2026.
Watch video →What's hot!
View all perspectives
What's Hot
What Happens when CAR-T Fails Managing Disease Recurrence
Dr. Alfred Kim discusses abstracts OP0076 and OP0333 presented at EULAR 2026.
Watch video →
‘Strong’ Treatment Predictions in Inflammatory Myositis
Dr. Janet Pope, reports on abstracts POS0264 and OP0166, presented at the 2026 EULAR meeting in London.
Watch video →
Imaging in Subclinical Psoriatic Arthritis
Dr. Antoni Chan discusses abstract OP068 presented at EULAR 2026.
Watch video →
Are we failing in the treatment of RA-ILD?
Dr. Janet Pope discusses treatment of RA-ILD after attending the "How to Treat (HOT)" session on RA-ILD at EULAR 2026.
Watch video →
PsA Potpourri: Probiotics & Head-to-Head Data
Dr. Peter Nash reports on abstracts POS0290 and LB0001 at EULAR 2026.
Watch video →
Combination Biologics in PsA: MRI Findings from AFFINITY
Dr. Artie Kavanaugh reports on abstract OP0186 presented at EULAR 2026 in London.
Watch video →
How Many CAR-Ts Do We Need to Test Drive?
Dr. Janet Pope reviews CAR-T therapy at 2026 EULAR 2026, and the issues and questions that remain with its use in rheumatology.
Watch video →
BMI Outranks Treatment in PsA Outcomes?
Dr. Peter Nash reports on abstract OP0187 presented at EULAR 2026 in London.
Watch video →
Dietary Interventions in PsA
Dr. Peter Nash reports on several abstracts at the 2026 EULAR meeting in London, including: OP069; OP070 and POS0050.
Watch video →
Low dose Blinatumomab: Many Relapse with an Unexpected Surprise
Dr. Alfred Kim discusses abstract OP0203 presented at EULAR 2026 in London.
Watch video →
RA BRIDGE and RA BRANCH trials: Baricitinib and VTE Risk
Drs. Mrinalini Dey and Jon Giles discuss abstract LB0009 presented at EULAR 2026 in London
Watch video →
Day 4 Recap: EULAR 2026
Join Drs. Jack Cush, Mrinalini Dey, Antoni Chan, and Yuz Yusof. Abstracts discussed included: LB0001 LB0002 LB0003 LB0005 LB0007 LB0009 RA Plenary POS1350.
Watch video →
EULAR 2026 Recommendations: Immunization
Dr. Jiha Lee reporting from EULAR 2026 in London.
Watch video →
Making Methotrexate More Effective
Dr. Jonathan Kay reports on abstract OP0206 and OP0207 presented at EULAR 2026 in London
Watch video →
Day 3 Recap: EULAR 2026
Join Drs. Jack Cush, Jiha Lee, Nelly Ziade, and Sheila Reyes for a lively discussion. Abstracts discussed included: OP0348 POS0290 OP0342 POS1068 POS0201 POS0288
Watch video →
5 years since Patient ID001: Progress on CAR-T Therapy in RMD
Five years on, are we closer to licensing of the first CAR-T therapy in rheumatic and musculoskeletal diseases (RMD)?
Read more →
Antoni Chan MD (Prof) synovialjoints
2 months 1 week ago
Psoriatic arthritis #PsA sessions raised important topics on intercepting arthritis in psoriasis, treating obesity as a disease target, synovial biopsy to guide treatment, molecular imaging to reveal subclinical disease. More tomorrow. #Rheumatology @RheumNow #EULAR2026
Dietary interventions are rarely taken as seriously as pharmacological therapies in rheumatology. Yet patients ask about them constantly, and an increasing number of studies suggest that nutrition may influence disease outcomes. Two randomized controlled trials presented at EULAR 2026 add to this growing literature in PsA and RA. However, before we start prescribing Mediterranean diets, the data deserve a closer look.
Antoni Chan MD (Prof) synovialjoints
2 months 1 week ago
Biopsy-guided treatment in PsA: match the drug to the tissue pathotype with 68% in LDA/remission vs 48% standard of care at 6 months. In myeloid CD117+ patients, mean DAPSA reduction at 6 months: IL-17i: −13.5, IL-23i: −12.8, TNFi: −7.5. Synovial biopsy with myeloid CD117+
Aurelie Najm AurelieRheumo
2 months 1 week ago
It's unclear whether GLP-1agonists inmpvove PsA from weight loss or other MoA
74 PsA patients on GLP-1RA vs 74 matched controls (BMI + disease activity matched)
After adjusting for BMI change PROs still improve cDAPSA (-0.4/mo) DAPSA (-0.6/mo) and pain but not SJC, TJC or CRP https://t.co/dcaU2jwbKJ
Few topics in rheumatology have reshaped prescribing behaviour as dramatically as the safety concerns surrounding JAK inhibitors following ORAL Surveillance and the subsequent FDA and EMA warnings.
Mrinalini Dey DrMiniDey
2 months 1 week ago
#OP0114 at #EULAR2026: Spanish study finds marked regional disparities in premature mortality from systemic connective tissue diseases. Higher socioeconomic deprivation and longer waits for specialist care were both linked to worse outcomes. @RheumNow https://t.co/04we2H0wdb
Aurelie Najm AurelieRheumo
2 months 1 week ago
ULT de-escalation in Gout: shall we do it?
Short answer: No
RCT 309 pts 24 mo
Primary outcome remission last 6 mo
79.2% ULT continuation vs 62.9% discontinuation p=0.002
Flare incidence 12% vs 32%
More NSAID/colchicine use after stopping ULT
Stopping ULT = urate rises quickly & https://t.co/bYKr5axu46
Janet Pope Janetbirdope
2 months 1 week ago
❎HIGH Type 1 #interferon
=
Worse #scleroderma
In both
#limited #lcSSc
&
#diffuse #dcSSc
Leeds cohort
?biomarker
#EULAR2026 @RheumNow ABST#POS1092
ABST#POS0395 https://t.co/cRrBIpLgP9
Md Yuzaiful Md Yusof Yuz6Yusof
2 months 1 week ago
#EULAR2026 OP0126 Long-term extension study up to 108 weeks: Ianalumab demonstrated sustained efficacy (change in ESSDAI) including those who switched from PBO to IAN in #Sjogren. IAN improved most domains apart from lungs, MSK & Haem - important to note @RheumNow #EULARBest https://t.co/x1d4G1s0jw
Mrinalini Dey DrMiniDey
2 months 1 week ago
#OP091 at #EULAR2026: RA was associated with a 44% higher risk of ischaemic stroke versus the general population, with higher stroke-related mortality and disability. Encouragingly, excess stroke risk was no longer significant in more recent RA cohorts. @RheumNow
Aurelie Najm AurelieRheumo
2 months 1 week ago
Izokibep IL-17A Affibody PsA
343 pts RCT PBO crossover wk16
52 wks data
ACR50 50–57% ACR70 36–42% PASI100 64% MDA 47–52%
No diff between QW vs Q2W
AE Injection-site reactions, URTIs most common
No new safety signals
Looks like any other IL17Ai to me
#EULAR2026 #OP073 https://t.co/WiHT8Plitn
Aurelie Najm AurelieRheumo
2 months 1 week ago
Can we intercept PsA?
Retro study 394 PSO pts 17 yrs follow-up 86 PsA
TNFi linked to higher PsA incidence vs IL- MoA
TNFi 45% vs IL-17i 14% vs IL-23i 10% vs IL-12/23i 11%
After adjustment IL-17i HR 0.35 IL-23i HR 0.17
Needs prospective confirmation!
#OP072 #EULAR2026 https://t.co/88RaukjLjY
Mrinalini Dey DrMiniDey
2 months 1 week ago
#OP090 at #EULAR2026: In this nationwide Danish study, RA patients with lung cancer had similar survival outcomes to patients without RA. Importantly, immune checkpoint inhibitor treatment did not appear to worsen outcomes in patients with pre-existing RA. @RheumNow
Antoni Chan MD (Prof) synovialjoints
2 months 1 week ago
At Week 52 with izokibep in #PsA PASI90: 63–69%; PASI100: 55–64%; MDA: 47–52%. The small-molecule format may enable deeper tissue penetration. Novel anti-IL-17 approach. Abstr#073 @RheumNow #EULAR2026 #Biologics https://t.co/IaJ1gyECZu
Antoni Chan MD (Prof) synovialjoints
2 months 1 week ago
Izokibep (novel small IL-17A inhibitor, 18.6 kDa) maintained efficacy to Week 52 in active #PsA with ~50% of patients achieving ACR50 and nearly half reaching MDA. Sustained durable response with no new safety signals Abstr#OP073 @RheumNow #EULAR2026 https://t.co/Y6fTirE886
